KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Discontinued Operations: 2010-2025

Historic Cash from Discontinued Operations for TherapeuticsMD (TXMD) over the last 4 years, with Sep 2025 value amounting to $47,000.

  • TherapeuticsMD's Cash from Discontinued Operations rose 141.23% to $47,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$28,000, marking a year-over-year increase of 99.16%. This contributed to the annual value of -$438,000 for FY2024, which is 98.25% up from last year.
  • Per TherapeuticsMD's latest filing, its Cash from Discontinued Operations stood at $47,000 for Q3 2025, which was up 182.46% from -$57,000 recorded in Q2 2025.
  • TherapeuticsMD's 5-year Cash from Discontinued Operations high stood at $136.7 million for Q2 2022, and its period low was -$24.5 million during Q1 2023.
  • Moreover, its 3-year median value for Cash from Discontinued Operations was -$57,000 (2025), whereas its average is -$2.3 million.
  • Over the last 5 years, TherapeuticsMD's Cash from Discontinued Operations had its largest YoY gain of 148.06% in 2023, and its largest YoY loss of 110.01% in 2023.
  • Over the past 4 years, TherapeuticsMD's Cash from Discontinued Operations (Quarterly) stood at $92.8 million in 2022, then crashed by 103.11% to -$2.9 million in 2023, then skyrocketed by 99.83% to -$5,000 in 2024, then spiked by 141.23% to $47,000 in 2025.
  • Its Cash from Discontinued Operations was $47,000 in Q3 2025, compared to -$57,000 in Q2 2025 and -$13,000 in Q1 2025.